Recombinant humanized (from mouse) antibody expressed in CHO binding to RSV glycoprotein F. Motavizumab is a humanized monoclonal antibody for the prevention of respiratory syncytial virus infection in high-risk infants.
Figure 1 Assessing the stability of pre-F during FI-RSV production.
(a) Dot blots demonstrate motavizumab recognition of antigenic site II, AM14 recognition of quaternary antigenic site V, and D25 and 5C4 recognition of antigenic site Ø after RSV is incubated at 37 °C with a 0.025% concentration of formalin in 24-hour intervals. Average antibody binding of virions is reported relative to antibody binding of a pre-F protein loading control with error bars representing standard deviation of three experiments. Significant differences between populations are calculated by One-Way ANOVA and noted graphically (ns, not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). Recognition of antigenic site II, present on both pre-F and post-F surfaces, is preserved after treatment with high temperature and a dilute concentration of formalin. In contrast, dot blots demonstrate pre-F-specific mAbs AM14, D25 and 5C4 rapidly lose reactivity against virions incubated at 37 °C with a dilute concentration of formalin. (b) Percentage of cells infected by RSV incubated at 37 °C with a 0.025% concentration formalin in 24-hour intervals by flow cytometry (Chen 2010).
Killikelly, A. M., Kanekiyo, M., & Graham, B. S. (2016). Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Scientific reports, 6, 34108.
Figure 2 AM14 is a prefusion-specific neutralizing antibody.
(A) Neutralization of laboratory strains and clinical isolates of RSV. Red bars are geometric means. (B) Binding of AM14 and motavizumab IgGs to immobilized RSV F proteins was measured using a Luminex system. (C) Binding of AM14 Fab to immobilized prefusion RSV F was measured by surface plasmon resonance. Best fit of the data to a 1:1 binding model is shown in red.
Gilman, M. S., Moin, S. M., Mas, V., Chen, M., Patel, N. K., Kramer, K., ... & Beaumont, T. (2015). Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS pathogens, 11(7), e1005035.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-RSV F ADCC Recombinant Antibody (Motavizumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to RSV glycoprotein F. Motavizumab is a humanized monoclonal antibody for the prevention of respiratory syncytial virus infection in high-risk infants.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-009 | Human Anti-RSV Recombinant Antibody (TAB-009) | IF, IP, Neut, FuncS, ELISA, FC, WB | IgG1 - kappa |
MRO-1209LC | Anti-HRSV F Recombinant Antibody (MEDI-493) | ELISA, Neut, PK | Humanized antibody |
MRO-1209LC-S(P) | Anti-HRSV F Recombinant Antibody scFv Fragment (MEDI-493) | ELISA | Humanized antibody |
MRO-1209LC-F(E) | Anti-HRSV F Recombinant Antibody Fab Fragment (MEDI-493) | ELISA | Humanized antibody |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-709, RRID: AB_3111987)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.